INVOKANA details covers drugs, mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details

INVOKANA Market Forecast INVOKANA drug Insight

&ldquo;INVOKANA Market Size, Forecast, and Market Insight - 2032&rdquo; report provides comprehensive insights about INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the INVOKANA in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 &ndash;2032 is provided in this report along with a detailed description of the INVOKANA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVOKANA market forecast analysis in the 7MM, SWOT, analysts&rsquo; views, comprehensive overview of market competitors, and brief about other emerging therapies.
<h2>Drug Summary</h2>
INVOKANA (canagliflozin) is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA, is the class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors, approved in the United States in 2013 (Janssen Pharmaceuticals, 2013). The label was expanded to cover more indications such as diabetic kidney disease in the subsequent years in the US along with EU and Japan.
&nbsp;
Dosage and administration
The recommended starting dose is 100 mg once daily, taken before the first meal of the day. The dose can be increased to 300 mg once daily in patients tolerating 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control. Dose adjustment for patients with renal impairment may be required.
&nbsp;
Mechanism of action
Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for most filtered glucose reabsorption from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), thereby increasing urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.
<h2>Scope of the Report&nbsp;</h2>
The report provides insights into:
<ul>
<li>A comprehensive product overview including the INVOKANA description, mechanism of action, dosage and administration, research and development activities in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).</li>
<li>Elaborated details on INVOKANA regulatory milestones and other development activities have been provided in this report.</li>
<li>The report also highlights the INVOKANA research and development activities in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) across the United States, Europe, and Japan.</li>
<li>The report also covers the patents information with expiry timeline around INVOKANA.</li>
<li>The report contains forecasted sales of INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) till 2032.</li>
<li>Comprehensive coverage of the late-stage emerging therapies for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).</li>
<li>The report also features the SWOT analysis with analyst views for INVOKANA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).</li>
</ul>
<h2>Methodology</h2>
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight&rsquo;s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
<h2>INVOKANA Analytical Perspective by DelveInsight</h2>
In-depth INVOKANA Market Assessment
This report provides a detailed market assessment of INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
&nbsp;
INVOKANA Clinical Assessment
The report provides the clinical trials information of INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.
<h2>Report Highlights&nbsp;&nbsp;</h2>
<ul>
<li>In the coming years, the market scenario for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp; &nbsp;</li>
<li>The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVOKANA dominance.</li>
<li>Other emerging products for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) are expected to give tough market competition to INVOKANA and launch of late-stage emerging therapies in the near future will significantly impact the market.&nbsp;</li>
<li>A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVOKANA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).</li>
<li>Our in-depth analysis of the forecasted sales data of INVOKANA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVOKANA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD).&nbsp;</li>
</ul>
<h2>Key Questions</h2>
<ul>
<li>What is the product type, route of administration and mechanism of action of INVOKANA?</li>
<li>What is the clinical trial status of the study related to INVOKANA in Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) and study completion date?</li>
<li>What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVOKANA development?</li>
<li>What are the key designations that have been granted to INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?</li>
<li>What is the forecasted market scenario of INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?</li>
<li>What are the forecasted sales of INVOKANA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?&nbsp;&nbsp;</li>
<li>What are the other emerging products available and how are these giving competition to INVOKANA for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?</li>
<li>Which are the late-stage emerging therapies under development for the treatment of Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)?</li>
</ul>

1. Report Introduction&nbsp;
2. INVOKANA Overview&nbsp;
2.1. Product Detail
2.2. Clinical Development&nbsp;
2.2.1. Clinical studies&nbsp;
2.2.2. Clinical trials information&nbsp;
2.2.3. Safety and efficacy
2.3. Regulatory Milestones
2.4. Other Developmental Activities&nbsp;&nbsp;
2.5. Product Profile&nbsp;&nbsp;
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)&nbsp;
5. INVOKANA Market Assessment&nbsp;
5.1. Market Outlook of INVOKANA
5.2. 7MM Analysis&nbsp;
5.2.1. Market Size of INVOKANA in the 7MM for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3. Country-wise Market Analysis&nbsp;
5.3.1. Market Size of INVOKANA in the United States for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.2. Market Size of INVOKANA in Germany for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.3. Market Size of INVOKANA in France for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.4. Market Size of INVOKANA in Italy for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.5. Market Size of INVOKANA in Spain for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.6. Market Size of INVOKANA in the United Kingdom for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)&nbsp;
5.3.7. Market Size of INVOKANA in Japan for Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD)
6. SWOT Analysis&nbsp;
7. Analysts&rsquo; Views&nbsp;
8. Appendix&nbsp;
8.1. Bibliography&nbsp;
8.2. Report Methodology&nbsp;
9. DelveInsight Capabilities&nbsp;
10. Disclaimer&nbsp;
11. About DelveInsight&nbsp;
12. Report Purchase Options

INVOKANA Market Size, Forecast, and Market Insight − 2032

INVOKANA Drug Insight and Market Forecast- 2032 report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition.